NEW YORK, Nov. 01, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Opus Bank (NASDAQ:OPB) securities between July 28, 2014 and October 17, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/opus-bank. There is no cost or obligation to you.
According to the complaint, during the Class Period, Opus Bank made false and/or misleading statements and/or failed to disclose that: (a) some of the Company’s loans were of low quality; (b) Opus Bank was over-representing the quality of the loans to the public; (c) the Company failed to properly account for the loans in violation of the Generally Accepted Accounting Principles; (d) the Company would be forced to recognize large charge-offs associated with the loans; (e) Opus Bank lacked adequate internal controls over accounting and financial reporting; and (f) as a result of the above, the Company’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Opus Bank you have until December 27, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/opus-bank.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


BP Nears $10 Billion Castrol Stake Sale to Stonepeak
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 



